Anixa Biosciences Inc (ANIX) Stock Price, Quote & News

Company Profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery pro...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 708 9808

Website: www.anixa.com

Address:

3150 Almaden Expressway, Suite 250, San Jose, United States

FoxySprout Feb. 19 at 11:04 PM

$ANIX

0 · Reply

PortfolioVestige Feb. 17 at 3:08 PM

$ANIX Anixa Biosciences develops cancer therapies focusing on CAR-T and vaccines, with early-stage pipeline and binary clinical catalysts.

1 · Reply

stockobserver51 Feb. 11 at 3:00 PM

$ANIX The same course game for days 🥱

0 · Reply

ScalperEdge Feb. 10 at 1:15 PM

$ANIX is a biotech (Anixa Biosciences) focused on oncology and virology; pipeline is early-stage and high-risk.

0 · Reply

Sharpeetrades Feb. 9 at 9:25 PM

$ANIX any news why up 4% in AH?

0 · Reply

Rideabull Feb. 9 at 9:02 PM

$ANIX Hard to believe I'm excited at the prospect of this getting back over $3. 🤦‍♂️

0 · Reply

DARKP00L Feb. 9 at 1:11 PM

$ANIX 08:09 on Feb. 09 2026 Anixa Biosciences Issues Update On Patient Outcomes Observed In Ongoing Phase 1 Ovarian Cancer CAR-T Clinical Trial, Following Regulatory Approval Of Protocol Amendment That Enables Substantial Dose Escalation #tradeideas

0 · Reply

bioinvestorrr Feb. 9 at 12:48 PM

$ANIX EXCLUSIVE: Anixa Biosciences $ANIX Reports Patient Data In Ovarian Cancer CAR-T Trial After Regulatory Approval; Says 'Multiple patients substantially exceed expected survival at low dose levels' https://x.com/benzinga/status/2020838039891968244?s=46&t=ZouZlHTF4W8218coMXrVjA

1 · Reply

BillionerOfKing Feb. 4 at 9:00 PM

$ANIX Current Stock Price: $2.91 Contracts to trade: $2.5 ANIX Feb 20 2026 Call Entry: $1.06 Exit: $1.90 ROI: 79% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

stockobserver51 Feb. 2 at 6:35 PM

$ANIX La confianza de los inversores en estas acciones ya no existe.

0 · Reply

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Feb 9, 2026, 8:00 AM EST - 14 days ago

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation

Feb 9, 2026, 7:31 AM EST - 14 days ago

EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues

Feb 2, 2026, 9:00 AM EST - 21 days ago

Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization

Jan 27, 2026, 8:30 AM EST - 27 days ago

Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology

Jan 21, 2026, 3:54 PM EST - 4 weeks ago

Water Tower Research Publishes Initiation of Coverage Report on Anixa Biosciences, Inc., “Anixa's T-Cell Innovations Show Breakthrough Potential in Solid Tumors”

Dec 15, 2025, 8:45 AM EST - 2 months ago

Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic

Dec 11, 2025, 6:02 PM EST - 2 months ago

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

Dec 10, 2025, 9:00 AM EST - 2 months ago

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025

Nov 17, 2025, 6:17 PM EST - 3 months ago

Anixa Biosciences, Inc. (ANIX) Discusses Differentiated CAR-T Therapy and Breast Cancer Vaccine Clinical Programs Transcript

Nov 17, 2025, 8:15 AM EST - 3 months ago

Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

Nov 12, 2025, 11:00 AM EST - 3 months ago

Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat

Nov 12, 2025, 9:00 AM EST - 3 months ago

Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s

Nov 10, 2025, 10:30 AM EST - 3 months ago

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025

Nov 5, 2025, 8:55 AM EST - 3 months ago

Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic

Oct 23, 2025, 8:45 AM EDT - 4 months ago

Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference

Oct 20, 2025, 8:25 AM EDT - 4 months ago

Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

Oct 7, 2025, 8:30 AM EDT - 4 months ago

Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial

Sep 22, 2025, 8:05 AM EDT - 5 months ago

Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium

Sep 8, 2025, 8:00 AM EDT - 6 months ago

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

Sep 2, 2025, 8:54 AM EDT - 6 months ago

Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 9:13 AM EDT - 6 months ago

Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 8:37 AM EDT - 6 months ago

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

Aug 18, 2025, 9:00 AM EDT - 6 months ago

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Aug 12, 2025, 8:05 AM EDT - 6 months ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Aug 8, 2025, 9:15 AM EDT - 7 months ago

Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference

Aug 4, 2025, 8:45 AM EDT - 7 months ago

Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial

Jul 30, 2025, 8:15 AM EDT - 7 months ago

Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology

Jul 24, 2025, 8:00 AM EDT - 7 months ago

Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s

Jul 15, 2025, 3:49 PM EDT - 7 months ago

Anixa Biosciences: Oncology Platform With Asymmetric Upside

Jul 9, 2025, 8:00 AM EDT - 8 months ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology

Jun 23, 2025, 8:00 AM EDT - 8 months ago

Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial

Jun 20, 2025, 7:30 AM EDT - 8 months ago

Anixa Biosciences to Host an Investor Webcast on June 26, 2025

Jun 10, 2025, 7:00 AM EDT - 9 months ago

Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage

Jun 9, 2025, 8:00 AM EDT - 9 months ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025

Jun 3, 2025, 7:25 AM EDT - 9 months ago

Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview

Jun 2, 2025, 7:00 AM EDT - 9 months ago

Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine

May 19, 2025, 8:00 AM EDT - 10 months ago

Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones

May 12, 2025, 8:00 AM EDT - 10 months ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 30, 2025, 8:00 AM EDT - 10 months ago

Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th

Apr 14, 2025, 8:00 AM EDT - 11 months ago

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio

Apr 9, 2025, 8:00 AM EDT - 11 months ago

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

Apr 1, 2025, 8:00 AM EDT - 11 months ago

Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th

Mar 25, 2025, 8:00 AM EDT - 11 months ago

Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th

Mar 10, 2025, 8:30 AM EDT - 1 year ago

Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

Mar 3, 2025, 8:00 AM EST - 1 year ago

Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th

Feb 26, 2025, 8:00 AM EST - 1 year ago

Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial

Feb 25, 2025, 7:30 AM EST - 1 year ago

Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"

FoxySprout Feb. 19 at 11:04 PM

$ANIX

0 · Reply

PortfolioVestige Feb. 17 at 3:08 PM

$ANIX Anixa Biosciences develops cancer therapies focusing on CAR-T and vaccines, with early-stage pipeline and binary clinical catalysts.

1 · Reply

stockobserver51 Feb. 11 at 3:00 PM

$ANIX The same course game for days 🥱

0 · Reply

ScalperEdge Feb. 10 at 1:15 PM

$ANIX is a biotech (Anixa Biosciences) focused on oncology and virology; pipeline is early-stage and high-risk.

0 · Reply

Sharpeetrades Feb. 9 at 9:25 PM

$ANIX any news why up 4% in AH?

0 · Reply

Rideabull Feb. 9 at 9:02 PM

$ANIX Hard to believe I'm excited at the prospect of this getting back over $3. 🤦‍♂️

0 · Reply

DARKP00L Feb. 9 at 1:11 PM

0 · Reply

bioinvestorrr Feb. 9 at 12:48 PM

1 · Reply

BillionerOfKing Feb. 4 at 9:00 PM

0 · Reply

stockobserver51 Feb. 2 at 6:35 PM

$ANIX La confianza de los inversores en estas acciones ya no existe.

0 · Reply

Buster67 Jan. 29 at 6:31 PM

$ANIX Momentum neither side

0 · Reply

Pedelco Jan. 29 at 1:17 PM

$ANIX back to 5$

1 · Reply

Rideabull Jan. 28 at 9:22 PM

$ANIX https://ir.anixa.com/sec-filings/content/0001493152-26-004035/formdef14a.htm They are overpaid. Results as measured by share price are abysmal. They should be embarrassed to collect this compensation. "We are asking our stockholders to indicate their support for our named executive officer compensation as described in this proxy statement. This “say-on-pay” proposal gives our stockholders the opportunity to express their views on our named executive officers’ compensation. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers described in this proxy statement. "

0 · Reply

WinPlaceShow Jan. 27 at 4:52 PM

$ANIX thinking this should lead to good things!! Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology https://share.google/64XeJcCwz1Yfr7WwI

1 · Reply

G101SPM Jan. 27 at 1:55 PM

$ANIX $3.02 bid. EXIT $8.00 Holding long position at loss https://stocktwits.com/G101SPM/message/608995692 BRIEF: Anixa Biosciences receives notice of allows from IMPI for patent covering breast cancer vaccine technology. note: Co announces that the Mexican Institute of Industrial Property (IMPI) has issued a Notice of Allowance for a new patent related to its breast cancer vaccine technology. This patent, exclusively licensed from Cleveland Clinic, will provide composition of matter protection for the Company's novel approach to breast cancer treatment and prevention in Mexico. The Mexican patent complements patents issued in the United States and other key global jurisdictions, and represents an important step toward future regulatory and commercial efforts outside the U.S.

0 · Reply

stockobserver51 Jan. 26 at 4:47 PM

$ANIX And now this! Last week we fell from the water tower, and now the withdrawal from the WHO, which affects the entire medical industry. "Unbelievable!"

1 · Reply

TimRegan_WTR Jan. 23 at 2:27 PM

$ANIX

0 · Reply

TimRegan_WTR Jan. 22 at 8:23 PM

$ANIX

0 · Reply

stockobserver51 Jan. 16 at 7:52 PM

$ANIX Despite brief resuscitation efforts, oxygen is lacking again.

0 · Reply

Pedelco Jan. 14 at 8:37 PM

$ANIX fuck cancer, Super bullish

0 · Reply

gziwiss Jan. 12 at 10:56 PM

$ANIX what cause delay on earning?

0 · Reply

d_risk Jan. 12 at 10:03 PM

$ANIX - Anixa Biosciences Inc. Common Stock - 10K - Updated Risk Factors ANIX flags heightened uncertainty around novel CAR-T development, tougher patient enrollment and vaccine hesitancy, new supply chain vulnerabilities for cell therapy inputs, and more complex trial, partnership, and IP litigation risks, while financial risk language stays largely the same aside from updated numbers. #Biotechnology #IntellectualProperty #SupplyChainRisk #ClinicalTrials #CellTherapy 🟢 Added 🟠 Removed https://d-risk.ai/ANIX/10-K/2026-01-12

0 · Reply

Market Cap	96.13M
Revenue (ttm)	0.00
Net Income (ttm)	-10.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	81,500
Avg Vol	321,746
Day's Range	N/A - N/A
Shares Out	33.38M
Stochastic %K	64%
Beta	0.53
Analysts	Strong Sell
Price Target	$10.00